RE:RE:RE:RE:RE:RE:RE:The Role of Oxygen, confirmed in Belgium
I was so wrapped up in this heady scientific thesis stuff [sic] that I almost forgot that we are only a few days away from the second quarter financial report being released. Should be an eye opener since for one thing the company will have had a full 6 months to show shareholders that the TLC-2000 is the real thing. Hopefully, investors can get a better sense of whether they will meet their guidance of $5M in sales for the device division by the end of 2016? Don't expect that figure to be after expenses since that would be asking for the moon too. They've pleaded with shareholders to be patient for a decade while they sorted out the technological details along with requiring the TLC-2000 be funded through shareholder dilution so now that it's up and running the onus is on Roger to demonstrate that the wait and expense was well worth it.
Cash reserves are always an issue with juniors so that item will be under close scrutiny and at the top of the agenda once again. Having enough cash to last until December in my view will be a hard sell with informed shareholders since they know that no company will risk causing a panic with their creditors by letting their reserves run dangerously close to dry. The TLC-2000 individual components alone would require that they have enough cash on hand to pay for the subcontracted parts when the bills come due. Assuring Health Canada that they are able to finance the phase 1b clinical trial to its full year long end would be another reason why they need to restock their cash reserves. All in all, it should be an interesting couple of weeks for investors when you throw in the speculation surrounding the ITA approval and if it will be rubber stamped by the end of this month.